Cargando…

Computationally repurposed drugs and natural products against RNA dependent RNA polymerase as potential COVID-19 therapies

Repurposing of existing drugs and drug candidates is an ideal approach to identify new potential therapies for SARS-CoV-2 that can be tested without delay in human trials of infected patients. Here we applied a virtual screening approach using Autodock Vina and molecular dynamics simulation in tande...

Descripción completa

Detalles Bibliográficos
Autores principales:	Piplani, Sakshi, Singh, Puneet Kumar, Winkler, David A., Petrovsky, Nikolai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Singapore 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8450033/ https://www.ncbi.nlm.nih.gov/pubmed/34766004 http://dx.doi.org/10.1186/s43556-021-00050-3

Ejemplares similares

Potential COVID-19 Therapies from Computational Repurposing of Drugs and Natural Products against the SARS-CoV-2 Helicase
por: Piplani, Sakshi, et al.
Publicado: (2022)

Computational Repurposing of Drugs and Natural Products Against SARS-CoV-2 Main Protease (M(pro)) as Potential COVID-19 Therapies
por: Piplani, Sakshi, et al.
Publicado: (2022)

Identifying SARS-CoV-2 Drugs Binding to the Spike Fatty Acid Binding Pocket Using In Silico Docking and Molecular Dynamics
por: Piplani, Sakshi, et al.
Publicado: (2023)

Author Correction: In silico comparison of SARS-CoV-2 spike protein-ACE2 binding affinities across species and implications for virus origin
por: Piplani, Sakshi, et al.
Publicado: (2021)

In silico comparison of SARS-CoV-2 spike protein-ACE2 binding affinities across species and implications for virus origin
por: Piplani, Sakshi, et al.
Publicado: (2021)

Repurposing of potential antiviral drugs against RNA-dependent RNA polymerase of SARS-CoV-2 by computational approach
por: Gangadharan, Sivakumar, et al.
Publicado: (2022)

Repurposing antiviral drugs against the human monkeypox virus DNA-dependent RNA polymerase; in silico perspective
por: Abduljalil, Jameel M., et al.
Publicado: (2022)

Repurposing FDA-approved phytomedicines, natural products, antivirals and cell protectives against SARS-CoV-2 (COVID-19) RNA-dependent RNA polymerase
por: Kandeel, Mahmoud, et al.
Publicado: (2020)

Targeting SARS-CoV-2 RNA-dependent RNA polymerase: An in silico drug repurposing for COVID-19
por: Baby, Krishnaprasad, et al.
Publicado: (2020)

SARS-CoV-2 RNA Dependent RNA polymerase (RdRp) – A drug repurposing study
por: Ahmad, Jamshaid, et al.
Publicado: (2020)

Drug repurposing for Mpox: Discovery of small molecules as potential inhibitors against DNA‐dependent RNA polymerase using molecular modeling approach
por: Dutt, Mansi, et al.
Publicado: (2023)

RNA-dependent RNA polymerase (RdRp) inhibitors: The current landscape and repurposing for the COVID-19 pandemic
por: Tian, Lei, et al.
Publicado: (2021)

Repurposing nonnucleoside antivirals against SARS-CoV2 NSP12 (RNA dependent RNA polymerase): In silico-molecular insight
por: Begum, Feroza, et al.
Publicado: (2021)

Drug repurposing against main protease and RNA-dependent RNA polymerase of SARS-CoV-2 using molecular docking, MM-GBSA calculations and molecular dynamics
por: Mohammed, Ahmed O., et al.
Publicado: (2022)

Rapid development of analytical methods for evaluating pandemic vaccines: a COVID-19 perspective
por: Baldwin, Jeremy, et al.
Publicado: (2021)

Prediction of potential inhibitors for RNA-dependent RNA polymerase of SARS-CoV-2 using comprehensive drug repurposing and molecular docking approach
por: Parvez, Md. Sorwer Alam, et al.
Publicado: (2020)

Raltegravir, Indinavir, Tipranavir, Dolutegravir, and Etravirine against main protease and RNA-dependent RNA polymerase of SARS-CoV-2: A molecular docking and drug repurposing approach
por: Indu, Purushothaman, et al.
Publicado: (2020)

Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach
por: Molavi, Zahra, et al.
Publicado: (2021)

Pharmacophore-Model-Based Drug Repurposing for the Identification of the Potential Inhibitors Targeting the Allosteric Site in Dengue Virus NS5 RNA-Dependent RNA Polymerase
por: Kumar, Sanjay, et al.
Publicado: (2022)

Repurposing FDA-approved drugs cetilistat, abiraterone, diiodohydroxyquinoline, bexarotene, and remdesivir as potential inhibitors against RNA dependent RNA polymerase of SARS-CoV-2: A comparative in silico perspective
por: Shahabadi, Nahid, et al.
Publicado: (2023)

Evolutionary connection between the catalytic subunits of DNA-dependent RNA polymerases and eukaryotic RNA-dependent RNA polymerases and the origin of RNA polymerases
por: Iyer, Lakshminarayan M, et al.
Publicado: (2003)

Exploration of natural compounds against the human mpox virus DNA-dependent RNA polymerase in silico
por: Abduljalil, Jameel M., et al.
Publicado: (2023)

Discovering Potential RNA Dependent RNA Polymerase Inhibitors as Prospective Drugs Against COVID-19: An in silico Approach
por: Saha, Satabdi, et al.
Publicado: (2021)

Identification of FDA-approved drugs against SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) through computational virtual screening
por: Jade, Dhananjay, et al.
Publicado: (2022)

Natural plant products as potential inhibitors of RNA dependent RNA polymerase of Severe Acute Respiratory Syndrome Coronavirus-2
por: Koulgi, Shruti, et al.
Publicado: (2021)

RNA-dependent RNA polymerase (RdRp) natural antiviral inhibitors: a review
por: Leite, Daniela Regina Buch, et al.
Publicado: (2022)

In silico evaluation of potential intervention against SARS-CoV-2 RNA-dependent RNA polymerase
por: Kapoor, Shreya, et al.
Publicado: (2023)

RNA-dependent RNA polymerase: Structure, mechanism, and drug discovery for COVID-19
por: Jiang, Yi, et al.
Publicado: (2021)

RNA-Dependent RNA Polymerase as a Target for COVID-19 Drug Discovery
por: Zhu, Wei, et al.
Publicado: (2020)

Repurposing Antiviral Drugs for Orthogonal RNA‐Catalyzed Labeling of RNA
por: Ghaem Maghami, Mohammad, et al.
Publicado: (2020)

Phylogenetic Analysis and Structural Perspectives of RNA-Dependent RNA-Polymerase Inhibition from SARs-CoV-2 with Natural Products
por: Khan, Abbas, et al.
Publicado: (2020)

Origin and Evolution of RNA-Dependent RNA Polymerase
por: de Farias, Savio T., et al.
Publicado: (2017)

RNA-dependent RNA polymerase 1 in potato (Solanum tuberosum) and its relationship to other plant RNA-dependent RNA polymerases
por: Hunter, Lydia J. R., et al.
Publicado: (2016)

Lipopeptides against COVID-19 RNA-dependent RNA polymerase using molecular docking
por: Xia, Bo, et al.
Publicado: (2021)

Fludarabine, a Potential DNA-Dependent RNA Polymerase Inhibitor, as a Prospective Drug against Monkeypox Virus: A Computational Approach
por: Altayb, Hisham N.
Publicado: (2022)

An in silico approach to target RNA-dependent RNA polymerase of COVID-19 with naturally occurring phytochemicals
por: Mahrosh, Hafiza Salaha, et al.
Publicado: (2021)

Advances in the computational landscape for repurposed drugs against COVID-19
por: Aronskyy, Illya, et al.
Publicado: (2021)

Rational Drug Design and Docking of the RNA Dependent RNA Polymerase Domain of NCoV
por: Kumar, Amit, et al.
Publicado: (2020)

In silico identification of promising inhibitor against RNA-dependent RNA polymerase target of SARS-CoV-2
por: Singh, Pushpendra, et al.
Publicado: (2021)

Evaluation of potential anti-RNA-dependent RNA polymerase (RdRP) drugs against the newly emerged model of COVID-19 RdRP using computational methods
por: Poustforoosh, Alireza, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_13vui6irsefs6nlck25qut8u8m